SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77502.12
579.48 (0.75%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V PT	225 Small Cap	11.85 (2.16%)	N/A	0.4	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Fabtech Technologies Ltd.	Q V PT	700 Small Cap	161.75 (2.73%)	29.65	1.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Anuh Pharma Ltd.	Q V PT	802 Small Cap	81.49 (1.88%)	19.9	2.32	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Shree Ganesh Remedies Ltd.	Q V PT	863 Small Cap	642.40 (-4.38%)	46.4	5.06	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Sigachi Industries Ltd.	Q V+ PT	896 Small Cap	23 (-1.96%)	N/A	1.85	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Kopran Ltd.	Q V PT	912 Small Cap	186.95 (-0.98%)	29.69	2.02	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Health X Platform Ltd.	Q V PT	1,009 Small Cap	311 (-1.91%)	N/A	3.65	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Wanbury Ltd.	Q V+ PT	1,007 Small Cap	286.85 (-0.47%)	15.15	6.94	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	1,033 Small Cap	131 (-0.04%)	104.32	4.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Fermenta Biotech Ltd.	Q V PT	1,043 Small Cap	350.95 (-1.00%)	16.07	2.44	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	3B Blackbio Dx Ltd.	Q V PT	1,028 Small Cap	1,207.75 (0.84%)	21.02	3.8	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Themis Medicare Ltd.	Q V PT	1,019 Small Cap	119.15 (7.73%)	N/A	4.09	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Bajaj Healthcare Ltd.	Q V PT	1,162 Small Cap	342.20 (-0.88%)	54.06	2.16	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Laxmi Dental Ltd.	Q V PT	1,226 Small Cap	224.85 (0.81%)	75.23	5	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Lincoln Pharmaceuticals Ltd.	Q V PT	1,244 Small Cap	625.45 (0.70%)	14.25	1.65	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	GPT Healthcare Ltd.	Q V PT	1,230 Small Cap	156.45 (4.40%)	30.41	4.76	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Syncom Formulations (India) Ltd.	Q V PT	1,355 Small Cap	14.25 (-1.18%)	17.62	3.25	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Suraksha Diagnostic Ltd.	Q V PT	1,397 Small Cap	271.30 (1.17%)	43.9	5.77	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Tarsons Products Ltd.	Q V+ PT	1,391 Small Cap	266.05 (1.78%)	62.47	2.1	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,566 Small Cap	235.20 (-1.13%)	35.94	6.52	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Windlas Biotech Ltd.	Q V PT	1,779 Small Cap	861.40 (-0.05%)	26.76	3.33	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Hester Biosciences Ltd.	Q V PT	1,866 Small Cap	2,178.65 (-0.67%)	35.57	4.81	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Krsnaa Diagnostics Ltd.	Q V PT	1,789 Small Cap	572.55 (3.79%)	18.31	1.89	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Shalby Ltd.	Q V PT	1,886 Small Cap	173.45 (-0.69%)	16.59	1.5	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,294 Small Cap	133.60 (-5.01%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Indoco Remedies Ltd.	Q V+ PT	2,186 Small Cap	243.35 (2.74%)	N/A	2.04	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,430 Small Cap	5,105.95 (1.56%)	35.2	7.13	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Fischer Medical Ventures Ltd.	Q V PT	2,681 Small Cap	39.08 (-4.59%)	N/A	8.19	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Vimta Labs Ltd.	Q V+ PT	2,606 Small Cap	586.10 (0.47%)	33.79	5.82	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Hikal Ltd.	Q V+ PT	2,697 Small Cap	223.15 (2.03%)	N/A	2.3	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Suven Life Sciences	298.65	8.92%
Themis Medicare	119.15	7.73%
Dishman Carbogen Amc	188	7%
Shilpa Medicare	600.85	5.26%
GPT Healthcare	156.45	4.40%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
KMC Speciality Hosp.	133.60	-5.01%
Morepen Laboratories	59.71	-4.63%
Fischer Medical	39.08	-4.59%
Shree Ganesh Remed.	642.40	-4.38%
Gufic Biosciences	385.40	-2.24%

News about Top Pharma Companies in India

Jul, 2026

Fabtech Technologies informs about outcome of postal ballot

Fabtech Technologies has informed that the Company had sought consent from members of the Company on the following resolutions through Postal Ballot notice dated May 25, 2026: Appointment of Rupal Dhiren Haria (DIN: 10624643) as a Non-Executive Independent Director of the Company; and Appointment of Bharti Khanna (DIN: 05147844) as a Non-Executive Independent Director of the Company. Based on the report issued by our Scrutinizer, CS Rachana Shanbhag, Partner of DA Kamat & Co., Company Secretaries, (FCS: 8227/ CP: 9297), the above resolutions have been passed and the same are deemed to have been approved on the last date of e-voting period i.e., Tuesday, June 30, 2026. The voting results in the format prescribed under Regulation 44(3) of SEBI. Listing. Regulations, along with the Scrutinizer's Report on remote e-voting, in respect of above resolutions are attached. The Voting Results along with the Scrutinizer's Report are available on the Company's website www.fabtechnologies.com and also on the website of NSDL at https://www.evoting.nsdl.com/.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Themis Medicare informs about disclosure

Themis Medicare has informed that the exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Windlas Biotech submits AGM notice

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III of the said Regulations, Windlas Biotech has informed that it enclosed a copy of the Notice of the 25th Annual General Meeting (AGM) of the Company scheduled to be held on Thursday, July 23, 2026 at 01.00 PM (IST) through Video Conferencing (VC)/Other Audio ,Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. ln compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company is pleased to provide to its Members, facility to exercise their right to vote at the 25th AGM scheduled to be held on July 23, 2026, by electronic means and the business mentioned in the AGM Notice may be transacted through e-voting services provided by MUFG Intime India at https://instavote.linkintime.co.in/. The Company has fixed July 16, 2026 as the ‘cut-off date’ for ascertaining the names of members, holding shares of the Company, who will be entitled to cast their votes electronically during July 20, 2026 (9:00 AM) to July 22, 2026 (5:00 PM) and also during AGM in respect of business to be transacted at the aforesaid AGM and for the purpose of receiving dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Vimta Labs informs about closure of trading window

Vimta Labs has informed that as per the provisions of the Company’s code of conduct for prevention of Insider Trading, the Trading Window for transactions in shares of the Company for all designated persons, their immediate relatives and all connected persons under the code will remain closed from 1stJuly 2026 till 48 hours post declaration of unaudited financial results of the Company for the first quarter ended 30th June 2026.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

The total consideration for 85% stake would be Rs 20.8 crore, which shall be funded from internal accruals of the company

Jun, 2026

Tarsons Products informs about trading window closure

Tarsons Products has informed that in terms of the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Tarsons Products (the Company) will remain closed for all Designated Persons and their immediate relatives with effect from Wednesday, July 01, 2026 until 48 hours after the declaration and dissemination of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. Accordingly, all the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of the Trading Window.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	225 Crore
2	Fabtech Technologies Ltd.	700 Crore
3	Anuh Pharma Ltd.	802 Crore
4	Shree Ganesh Remedies Ltd.	863 Crore
5	Sigachi Industries Ltd.	896 Crore
6	Kopran Ltd.	912 Crore
7	Health X Platform Ltd.	1,009 Crore
8	Wanbury Ltd.	1,007 Crore
9	Gujarat Kidney And Super Speciality Ltd.	1,033 Crore
10	Fermenta Biotech Ltd.	1,043 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	25.35
Lupin Ltd. (M)	Somewhat Good	2,399	1,09,576	20.55	4.88	11.89	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,525	80,692	101
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	41.28
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	39.25
Aurobindo Pharma Ltd. (M)	Very Good	1,560	89,345	34.75
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	31.18
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	54.70	9.13	33.13	15.51
Mankind Pharma Ltd. (M)	Very Good	2,487	1,02,844	50.47	6.27	31.70	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	13.26
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,872	4,47,704	39.00	5.36	22.34	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	22.29
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	18.78
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,195	60,890	44.71	5.79	11.86	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Fabtech Technologies informs about outcome of postal ballot

Themis Medicare informs about disclosure

Windlas Biotech submits AGM notice

Vimta Labs informs about closure of trading window

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

Tarsons Products informs about trading window closure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.